Korean biotech Mepsgen has launched NanoCalibur GMP, an automated system for large-scale nanoparticle production, aimed at preclinical and clinical drug development.

The system encapsulates mRNA, antisense oligonucleotides, and other drug candidates into lipid nanoparticles and lipid-polymer nanoparticles with high efficiency. 

Unlike syringe-based devices, Mepsgen says NanoCalibur GMP integrates a mass flow controller for real-time monitoring and synthesis adjustments, ensuring consistent, high-quality production. It also includes a clean-in-place function, eliminating downtime for disassembly and manual cleaning.

The launch follows the October rollout of NanoCalibur Lab, a benchtop model used in universities and hospital research centers. Mepsgen says domestic pharmaceutical firms have already placed pre-orders, positioning the new system for early adoption.

CEO Kim Yong-tae added that the GMP-grade system is built to scale up nanoparticle-based drug manufacturing efficiently. “We’re delivering an automated, GMP-compliant platform that enhances both production efficiency and quality,” he said.

Mepsgen plans to publish research on optimized shear force parameters for nanoparticle stability and is developing single-use plastic chips to expand its product offerings.